Literature DB >> 10828654

Increased cerebrospinal fluid tau protein in multiple sclerosis.

E Kapaki1, G P Paraskevas, M Michalopoulou, K Kilidireas.   

Abstract

Axonal damage is now being recognized as a common finding in multiple sclerosis (MS) lesions and a cause of irreversible neurological damage. Attempts to identify markers of early axonal damage are of great significance. This prompted us to examine the microtubule-associated protein tau in the cerebrospinal fluid (CSF) of patients with MS vs. controls. Tau was measured by double antibody sandwich ELISA. Increased CSF tau levels were found in MS as compared to controls (medians 249.6 and 135 pg/ml respectively, p<0.001). Half of the MS patients presented with levels above the upper limit of the controls. A significant increase vs. controls was found in both relapsing-remitting and progressive subtypes. These data may indicate axonal impairment in a subpopulation of MS patients and may provide a tool for the estimation of axonal damage during life. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828654     DOI: 10.1159/000008181

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  17 in total

1.  The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis.

Authors:  H Bartosik-Psujek; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

Review 2.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 3.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 4.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

5.  Axonal damage in multiple sclerosis.

Authors:  Jeffery D Haines; Matilde Inglese; Patrizia Casaccia
Journal:  Mt Sinai J Med       Date:  2011 Mar-Apr

6.  Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.

Authors:  Eleonora Virgilio; Domizia Vecchio; Ilaria Crespi; Chiara Puricelli; Paolo Barbero; Giulia Galli; Roberto Cantello; Umberto Dianzani; Cristoforo Comi
Journal:  J Neurol       Date:  2022-01-28       Impact factor: 4.849

Review 7.  [Dementia as a primary symptom in late onset multiple sclerosis. Case series and review of the literature].

Authors:  T Leyhe; C Laske; G Buchkremer; H Wormstall; H Wiendl
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

Review 8.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

9.  Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy.

Authors:  Jacek Jaworski; Marek Psujek; Marzena Janczarek; Małgorzata Szczerbo-Trojanowska; Halina Bartosik-Psujek
Journal:  Ups J Med Sci       Date:  2012-05-04       Impact factor: 2.384

10.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.